Context Therapeutics Stock Performance
| CNTX Stock | USD 0.71 0.06 9.23% |
The firm shows a Beta (market volatility) of 1.87, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Context Therapeutics will likely underperform. At this point, Context Therapeutics has a negative expected return of -0.82%. Please make sure to confirm Context Therapeutics' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Context Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Context Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors | 01/13/2025 |
2 | Franklin Resources Inc. Acquires Additional Shares in Context Therapeutics Inc. - GuruFocus.com | 01/27/2025 |
3 | Acquisition by Martin Lehr of 802700 shares of Context Therapeutics at 0.81 subject to Rule 16b-3 | 02/13/2025 |
4 | Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 02/24/2025 |
5 | Context Therapeutics Grants Stock Options to New Employees - MyChesCo | 02/25/2025 |
6 | Acquisition by Minai-azary Jennifer Lynn of 371800 shares of Context Therapeutics at 0.81 subject to Rule 16b-3 | 02/28/2025 |
7 | Acquisition by Minai-azary Jennifer Lynn of 52753 shares of Context Therapeutics at 5.59 subject to Rule 16b-3 | 03/07/2025 |
| Begin Period Cash Flow | 35.5 M |
Context |
Context Therapeutics Relative Risk vs. Return Landscape
If you would invest 129.00 in Context Therapeutics on December 17, 2024 and sell it today you would lose (58.00) from holding Context Therapeutics or give up 44.96% of portfolio value over 90 days. Context Therapeutics is currently does not generate positive expected returns and assumes 6.0475% risk (volatility on return distribution) over the 90 days horizon. In different words, 53% of stocks are less volatile than Context, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Context Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Context Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Context Therapeutics, and traders can use it to determine the average amount a Context Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.135
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CNTX |
Estimated Market Risk
| 6.05 actual daily | 53 53% of assets are less volatile |
Expected Return
| -0.82 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Context Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Context Therapeutics by adding Context Therapeutics to a well-diversified portfolio.
Context Therapeutics Fundamentals Growth
Context Stock prices reflect investors' perceptions of the future prospects and financial health of Context Therapeutics, and Context Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Context Stock performance.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | (30.66 M) | ||||
| Shares Outstanding | 75 M | ||||
| Price To Book | 0.64 X | ||||
| EBITDA | (25.06 M) | ||||
| Net Income | (23.96 M) | ||||
| Cash And Equivalents | 42.92 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 4.19 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.64 X | ||||
| Book Value Per Share | 1.12 X | ||||
| Cash Flow From Operations | (21.05 M) | ||||
| Earnings Per Share | (0.88) X | ||||
| Market Capitalization | 52.95 M | ||||
| Total Asset | 16.06 M | ||||
| Retained Earnings | (68.05 M) | ||||
| Working Capital | 11.86 M | ||||
About Context Therapeutics Performance
Evaluating Context Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Context Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Context Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.34) | (1.41) | |
| Return On Capital Employed | (2.43) | (2.31) | |
| Return On Assets | (1.34) | (1.41) | |
| Return On Equity | (2.32) | (2.21) |
Things to note about Context Therapeutics performance evaluation
Checking the ongoing alerts about Context Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Context Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Context Therapeutics generated a negative expected return over the last 90 days | |
| Context Therapeutics has high historical volatility and very poor performance | |
| Context Therapeutics has some characteristics of a very speculative penny stock | |
| Context Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (23.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Context Therapeutics currently holds about 42.92 M in cash with (21.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Context Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Context Therapeutics Grants Stock Options to New Employees - MyChesCo |
- Analyzing Context Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Context Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Context Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Context Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Context Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Context Therapeutics' stock. These opinions can provide insight into Context Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.